JP2024023235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023235A5 JP2024023235A5 JP2023189307A JP2023189307A JP2024023235A5 JP 2024023235 A5 JP2024023235 A5 JP 2024023235A5 JP 2023189307 A JP2023189307 A JP 2023189307A JP 2023189307 A JP2023189307 A JP 2023189307A JP 2024023235 A5 JP2024023235 A5 JP 2024023235A5
- Authority
- JP
- Japan
- Prior art keywords
- oligomeric compound
- stranded oligomeric
- modified oligonucleotide
- wing segment
- stranded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 108091034117 Oligonucleotide Proteins 0.000 claims 10
- 239000002777 nucleoside Substances 0.000 claims 10
- 125000003835 nucleoside group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102100037242 Amiloride-sensitive sodium channel subunit alpha Human genes 0.000 claims 2
- 101710194189 Amiloride-sensitive sodium channel subunit alpha Proteins 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- NETGOEWJJZQLCO-PKLMIRHRSA-N N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical group C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O.FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 NETGOEWJJZQLCO-PKLMIRHRSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579640P | 2017-10-31 | 2017-10-31 | |
| US62/579,640 | 2017-10-31 | ||
| US201862743669P | 2018-10-10 | 2018-10-10 | |
| US62/743,669 | 2018-10-10 | ||
| JP2020523976A JP7431728B2 (ja) | 2017-10-31 | 2018-10-31 | ＥＮａＣ発現の調節因子 |
| PCT/US2018/058354 WO2019089692A1 (en) | 2017-10-31 | 2018-10-31 | MODULATORS OF ENaC EXPRESSION |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523976A Division JP7431728B2 (ja) | 2017-10-31 | 2018-10-31 | ＥＮａＣ発現の調節因子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024023235A JP2024023235A (ja) | 2024-02-21 |
| JP2024023235A5 true JP2024023235A5 (enExample) | 2024-05-14 |
Family
ID=66333370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523976A Active JP7431728B2 (ja) | 2017-10-31 | 2018-10-31 | ＥＮａＣ発現の調節因子 |
| JP2023189307A Pending JP2024023235A (ja) | 2017-10-31 | 2023-11-06 | ＥＮａＣ発現の調節因子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523976A Active JP7431728B2 (ja) | 2017-10-31 | 2018-10-31 | ＥＮａＣ発現の調節因子 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20210180057A1 (enExample) |
| EP (1) | EP3703702A4 (enExample) |
| JP (2) | JP7431728B2 (enExample) |
| KR (1) | KR20200079505A (enExample) |
| CN (1) | CN111372594A (enExample) |
| AU (1) | AU2018357932A1 (enExample) |
| BR (1) | BR112020005038A2 (enExample) |
| CA (1) | CA3074739A1 (enExample) |
| CL (1) | CL2020000586A1 (enExample) |
| CO (1) | CO2020003134A2 (enExample) |
| IL (1) | IL274231A (enExample) |
| MX (1) | MX2020003554A (enExample) |
| PE (1) | PE20200749A1 (enExample) |
| SG (1) | SG11202001863PA (enExample) |
| TW (1) | TW201927313A (enExample) |
| WO (1) | WO2019089692A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230159920A1 (en) * | 2019-06-26 | 2023-05-25 | Fred Hutchinson Cancer Research Center | Methods and compositions comprising brd9 activating therapies for treating cancers and related disorders |
| WO2021021673A1 (en) * | 2019-07-26 | 2021-02-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gfap |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| EP2304057B1 (en) * | 2008-06-17 | 2014-09-17 | Signature Diagnostics AG | Method for the detection of ovarian cancer |
| US9574193B2 (en) * | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
| US10590485B2 (en) * | 2014-05-29 | 2020-03-17 | Geneticure Llc | Therapeutic regimen for hypertension |
-
2018
- 2018-10-31 CA CA3074739A patent/CA3074739A1/en not_active Abandoned
- 2018-10-31 KR KR1020207014550A patent/KR20200079505A/ko not_active Ceased
- 2018-10-31 EP EP18874475.9A patent/EP3703702A4/en active Pending
- 2018-10-31 SG SG11202001863PA patent/SG11202001863PA/en unknown
- 2018-10-31 AU AU2018357932A patent/AU2018357932A1/en not_active Abandoned
- 2018-10-31 TW TW107138481A patent/TW201927313A/zh unknown
- 2018-10-31 JP JP2020523976A patent/JP7431728B2/ja active Active
- 2018-10-31 BR BR112020005038-5A patent/BR112020005038A2/pt not_active Application Discontinuation
- 2018-10-31 MX MX2020003554A patent/MX2020003554A/es unknown
- 2018-10-31 CN CN201880058494.5A patent/CN111372594A/zh active Pending
- 2018-10-31 PE PE2020000308A patent/PE20200749A1/es unknown
- 2018-10-31 WO PCT/US2018/058354 patent/WO2019089692A1/en not_active Ceased
- 2018-10-31 US US16/759,908 patent/US20210180057A1/en not_active Abandoned
-
2020
- 2020-03-06 CL CL2020000586A patent/CL2020000586A1/es unknown
- 2020-03-16 CO CONC2020/0003134A patent/CO2020003134A2/es unknown
- 2020-04-26 IL IL274231A patent/IL274231A/en unknown
-
2023
- 2023-10-23 US US18/492,683 patent/US20240327838A1/en not_active Abandoned
- 2023-11-06 JP JP2023189307A patent/JP2024023235A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023235A5 (enExample) | ||
| Pley et al. | Model for an RNA tertiary interaction from the structure of an intermolecular complex between a GAAA tetraloop and an RNA helix | |
| ES2266402T3 (es) | L-nucleosidos para el tratamiento del virus de la hepatitis b y el virus de epstein-barr. | |
| EP0707481B1 (en) | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis b (hbv) and anti-hiv agents | |
| KR100587747B1 (ko) | Ｃ형 간염 바이러스에 의해 매개되는 질환의 치료를 위한4'-치환된 뉴클레오시드 | |
| CN100387237C (zh) | 用于治疗乙型肝炎的β-L-2'-脱氧-核苷 | |
| US5631239A (en) | L-2',3'-dideoxy nucleoside analogs as anti-Hepatitis B (HBV) agents | |
| US5756478A (en) | Method for reducing toxicity of D-nucleoside analogs with L-nucleosides | |
| JP2022106727A5 (enExample) | ||
| JP2018126141A5 (enExample) | ||
| TW202113079A (zh) | 經修飾之間隙子寡核苷酸及其使用方法 | |
| JPH06500012A (ja) | ウィルス（ｈｉｖ）増殖抑制 | |
| JP2022501024A5 (enExample) | ||
| JP2024516096A5 (enExample) | ||
| JP2022526267A5 (enExample) | ||
| JP2021520804A5 (enExample) | ||
| Lee et al. | Sequence-specific, strand-selective, and directional binding of neocarzinostatin chromophore to oligodeoxyribonucleotides | |
| JP2023528435A5 (enExample) | ||
| CN119032175A (zh) | 经修饰的间隔体寡聚物及其使用的方法 | |
| JP2021500903A5 (enExample) | ||
| JP2025509552A5 (enExample) | ||
| Porumb et al. | Triple-helices targeted to the polypurine tract of a murine retrovirus | |
| JP2023501352A5 (enExample) | ||
| JPWO2023112931A5 (enExample) | ||
| US6319711B1 (en) | Composition and method for inhibiting reverse transcript of a retrovirus |